SDHD is altered in 0.14% of gastrointestinal stromal tumor patients [3].

SDHD is an inclusion criterion in 5 clinical trials for gastrointestinal stromal tumor, of which 3 are open and 2 are closed. Of the trials that contain SDHD status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1 (0 open) and 4 are phase 2 (3 open) [4].

SDHD is altered in 0.3% of renal cell carcinoma patients [3].

SDHD is an inclusion criterion in 4 clinical trials for renal cell carcinoma, of which 1 is open and 3 are closed. Of the trials that contain SDHD status and renal cell carcinoma as inclusion criteria, 1 is phase 1 (0 open), 1 is phase 1/phase 2 (0 open), and 2 are phase 2 (1 open) [4].

SDHD is altered in 0.45% of malignant solid tumor patients [3].

SDHD is an inclusion criterion in 2 clinical trials for malignant solid tumor, of which 1 is open and 1 is closed. Of the trials that contain SDHD status and malignant solid tumor as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [4].

SDHD is altered in 1.52% of paraganglioma patients [3].

SDHD is an inclusion criterion in 1 clinical trial for paraganglioma, of which 0 are open and 1 is closed. Of the trial that contains SDHD status and paraganglioma as inclusion criteria, 1 is phase 2 (0 open) [4].

SDHD is altered in 0.77% of papillary renal cell carcinoma patients [3].

SDHD is an inclusion criterion in 1 clinical trial for papillary renal cell carcinoma, of which 0 are open and 1 is closed. Of the trial that contains SDHD status and papillary renal cell carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].

SDHD is altered in 0.62% of pleural mesothelioma patients [3].

SDHD is an inclusion criterion in 1 clinical trial for pleural mesothelioma, of which 0 are open and 1 is closed. Of the trial that contains SDHD status and pleural mesothelioma as inclusion criteria, 1 is phase 1 (0 open) [4].

SDHD is altered in 0.37% of non-small cell lung carcinoma patients [3].

SDHD is an inclusion criterion in 1 clinical trial for non-small cell lung carcinoma, of which 0 are open and 1 is closed. Of the trial that contains SDHD status and non-small cell lung carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].

SDHD is altered in 0.28% of clear cell renal cell carcinoma patients [3].

SDHD is an inclusion criterion in 1 clinical trial for clear cell renal cell carcinoma, of which 0 are open and 1 is closed. Of the trial that contains SDHD status and clear cell renal cell carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].

SDHD is altered in 0.43% of breast carcinoma patients [3].

SDHD is an inclusion criterion in 1 clinical trial for breast carcinoma, of which 0 are open and 1 is closed. Of the trial that contains SDHD status and breast carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].

SDHD is altered in 0.29% of sarcoma patients [3].

SDHD is an inclusion criterion in 1 clinical trial for sarcoma, of which 1 is open and 0 are closed. Of the trial that contains SDHD status and sarcoma as inclusion criteria, 1 is phase 2 (1 open) [4].

SDHD is an inclusion criterion in 1 clinical trial for hereditary leiomyomatosis and renal cell cancer, of which 0 are open and 1 is closed. Of the trial that contains SDHD status and hereditary leiomyomatosis and renal cell cancer as inclusion criteria, 1 is phase 2 (0 open) [4].

SDHD is an inclusion criterion in 1 clinical trial for leiomyosarcoma, of which 1 is open and 0 are closed. Of the trial that contains SDHD status and leiomyosarcoma as inclusion criteria, 1 is phase 2 (1 open) [4].

SDHD is an inclusion criterion in 1 clinical trial for osteosarcoma, of which 1 is open and 0 are closed. Of the trial that contains SDHD status and osteosarcoma as inclusion criteria, 1 is phase 2 (1 open) [4].

SDHD is an inclusion criterion in 1 clinical trial for peritoneal mesothelioma, of which 0 are open and 1 is closed. Of the trial that contains SDHD status and peritoneal mesothelioma as inclusion criteria, 1 is phase 1 (0 open) [4].